Obesity/Overweight – Unmet Need – Detailed, Expanded Analysis (US/EU)

Obesity is a significant public health concern in the United States and Europe. Its chronic progression is associated with type 2 diabetes and adverse cardiovascular (CV) health. Since 2012, several novel branded drugs have entered the market with varying degrees of commercial success. Approved agents include Novo Nordisk’s Wegovy (semaglutide) and Saxenda (liraglutide), Vivus’s Qsymia (phentermine / topiramate), and Nalpropion Pharmaceuticals’ Contrave (naltrexone / bupropion). In this report, endocrinologists compare current antiobesity drugs and discuss the attributes that the next generation of drugs should have to serve this medically important population and to succeed commercially in a potentially lucrative market.


  • How do endocrinologists rate current antiobesity drugs, such as Novo Nordisk’s Wegovy and Saxenda?
  • What drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
  • What trade-offs across different clinical attributes and prices are needed from new obesity drugs to be preferred by endocrinologists?
  • How can less-frequent dosing, route of administration, cardiovascular and renal benefit, and efficacy influence physician preference? Discover the answers with Clarivate’s fully customizable Target Product Profile (TPP) simulator.


Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP Simulator.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 31 European endocrinologists fielded in March 2023

Key companies: Novo Nordisk, Vivus, Currax Pharmaceuticals, Orexigen Therapeutics

Key drugs: Wegovy, Saxenda, Qsymia, Contrave/Mysimba, Xenical, phentermine

Table of contents

launch Related Market Assessment Reports